TrialSignal
Clinical trial intelligence report
A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 18, 2026
NCT ID
NCT02862431
Status
TERMINATED
Phase
Phase 1
Sponsor
Janssen Research & Development, LLC
Executive brief
Investment-Ready Snapshot
JNJ-64565111, developed by Janssen Research & Development, LLC, is currently in Phase 1 clinical trials aimed at assessing its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with Type 2 Diabetes Mellitus (T2DM). The termination of the study due to manufacturing-related issues raises concerns about the asset's viability and potential market entry. The T2DM market is highly competitive, with numerous established therapies and emerging candidates. Janssen's ability to navigate these manufacturing challenges and successfully reposition JNJ-64565111 will be critical for its commercial prospects. The asset's future will depend on addressing these issues and demonstrating clear clinical benefits over existing treatments.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02862431
Indication
Diabetes Mellitus, Type 2
Modality
small molecule
Target
Not specified in the provided data. Further investigation required to determine the precise molecular or mechanistic target profile of JNJ-64565111.
Intervention
JNJ-64565111, Placebo
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.